[CAS NO. 3778-73-2]  Ifosfamide

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [3778-73-2]

Catelog
HY-17419
Brand
MCE
CAS
3778-73-2

DESCRIPTION [3778-73-2]

Overview

MDLMFCD00057374
Molecular Weight261.09
Molecular FormulaC7H15Cl2N2O2P
SMILESClCCN1P(OCCC1)(NCCCl)=O

For research use only. We do not sell to patients.


Summary

Ifosfamide is an alkylating chemotherapeutic agent with activity against a wide range of tumors.


IC50 & Target

DNA Alkylator [1]


In Vitro

Ifosfamide is an alkylating chemotherapeutic agent with activity against a wide range of tumors [1] . Ifosfamide is activated by the cytochrome P450 family. Ifosfamide (0-5 mM) suppresses the viability of CYP2B1-expressing C8III-1 cells, while it is cytotoxic to the non-CYP2B1-expressing CrFK cells only at high concentration (5 mM) [2] . CYP BM3 mutants activates Ifosfamide, and Ifosfamide shows inhibitory activity against human U2OS cells [3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

Ifosfamide (50 mg/kg, i.p.) treatment before mating increases percentage of post-implantation loss and resorbs fetuses in pregnant rats. Ifosfamide also (50 mg/kg, i.p.) decreases the progesterone in the serum of pregnant rats. However, Ifosfamide causes no obvious difference with the control rats at 25 mg/kg. Ifosfamide (25, 50 mg/kg, i.p.) induces apoptosis and histological changes in the placentas and prenatal rats, most sensitive fetal organs are the brain, liver and kidney [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT01102608 Grupo Espanol de Investigacion en Sarcomas
Soft Tissue Sarcoma
March 2008 Phase 2
NCT00002526 Swiss Group for Clinical Cancer Research
Ovarian Cancer|Sarcoma
January 1993 Phase 2
NCT00001300 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sarcoma
June 1992 Phase 3

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)


Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL ( 191.50 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.8301 mL 19.1505 mL 38.3010 mL
5 mM 0.7660 mL 3.8301 mL 7.6602 mL
10 mM 0.3830 mL 1.9150 mL 3.8301 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 0.5% CMC-Na /saline water

    Solubility: 25 mg/mL (95.75 mM); Clear solution; Need ultrasonic

  • 2.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.5 mg/mL (9.58 mM); Clear solution

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (9.58 mM); Clear solution

  • 4.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.5 mg/mL (9.58 mM); Clear solution

* All of the co-solvents are available by MCE.


Synonyms

2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
A 4942
3-(2-Chloroethyl)-2-(2-chloroethylamino)tetrahydro-2H-1,3,2-oxaazaphosphorin 2-oxide
Ifosfamide
3-(2-Chloroethyl)-2-(2-chloroethylamino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Asta Z 4942
Isoendoxan
Isophosphamide
NSC 109724
Ifosfamid
Iphosphamide
3-(2-Chloroethyl)-2-(2-chloroethylamino)tetrahydro-2H-1,3,2-oxazaphosphorin 2-oxide
Holoxan 1000
Isofosfamide
Z 4942
Ifomide
Ifosphamide
Mitoxana
Holoxan
(±)-Ifosfamide
Cyfos
Naxamide
Ifex
MJF 9325
Ifosfomide
(2-Chloro-ethyl)-[3-(2-chloro-ethyl)-2-oxo-2λ*5*-[1,3,2]oxazaphosphinan-2-yl]-amine